US Supreme Court to decide on immunity for generic drug industry

If the US Supreme Court grants the generic drug industry immunity for failing to warn of their drugs’ possible side- effects, patients will face a much greater risk in suffering injuries, according to the American Association for Justice (AAJ). It said a result in favour of the drug industry could eliminate any incentive for generic manufacturers to ensure their drug is safe and adequately warns consumers of potential dangers.